Clinical Trial Update: Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating 5-azacitidine (Vidaza) for treatment of imminent hematologic relapse in patients with acute myeloid leukemia or myelodysplastic syndr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Status: COMPLETED